论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
长非编码 RNA SLC25A21-AS1 通过调节 miR-324-3p/IL-6 轴促进鼻咽癌多药耐药性
Authors Wang X, Wang C, Xu H, Xie H
Received 28 February 2020
Accepted for publication 23 April 2020
Published 26 May 2020 Volume 2020:12 Pages 3949—3957
DOI https://doi.org/10.2147/CMAR.S251820
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Background: Nasopharyngeal carcinoma (NPC), one of the most common types of head and neck tumor, occurred in the epithelial lining of the nasopharynx and is mainly prevalent in Southeast Asia and Southern China. However, the molecular mechanisms of NPC multidrug resistance still remained largely unclear.
Methods: The qRT-PCR assay was performed to examine SLC25A21-AS1, miR-324-3p and IL-6 expression in NPC tissues and cell. The CCK8 assay and colony formation assay were used to detect cell growth. In addition, CCK8 assay was performed to detect IC50 values of different drugs in NPC cell.
Results: In this study, we found that SLC25A21-AS1 expression was increased in NPC tissues and cell line, and knockdown of SLC25A21-AS1 inhibited cell growth and MDR in NPC cell. Moreover, SLC25A21-AS1 acted as a ceRNA for miR-324-3p and facilitates NPC cell growth and MDR by regulating the miR-324-3p/IL-6 axis.
Conclusion: Our findings demonstrated the role of SLC25A21-AS1/miR-324-3p/IL-6 axis in cell growth and MDR in NPC, which might be a potential prognostic and diagnostic marker in NPC patients and provide new insight into the molecular mechanism of MDR in NPC chemotherapy.
Keywords: SLC25A21-AS1, cell growth, MDR, miR-324-3p, IL-6
